Developer docs
API playgroundTry for free, no card

Search company profiles

Kane Biotech

Full company profile

uuid0002hd1

Namestring
Kane Biotech
Legal namestring
Kane Biotech Inc.
Websiteurl
kanebiotech.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Kane Biotech Inc. is a Canadian biotechnology company headquartered in Winnipeg, Manitoba, that develops and commercializes technologies to prevent and disperse microbial biofilms in human wound care. The company's commercial portfolio centers on the revyve® product line, which combines a proprietary coactiv+® antimicrobial platform with thermo-reversible gel chemistry that transitions from liquid to gel at body temperature for easy application, wound adherence, and atraumatic removal. The revyve portfolio comprises three FDA 510(k)-cleared products (Antimicrobial Wound Gel, Antimicrobial Wound Gel Spray, and Antimicrobial Skin and Wound Cleanser) and two Health Canada approvals, targeting chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcers), burn wounds, and surgical sites. The company also develops the DispersinB® enzyme for biofilm disruption and acquired FB Dermatology's FLETECH tissue regeneration technology in January 2025.

The business model is a regulated medical device sales operation in early commercialization, generating revenue through one-time product sales of FDA-cleared wound care products via a multi-channel distribution model. As of Q1 2026, Kane Biotech had signed non-exclusive distribution and sales agent agreements with Marathon Medical Corporation (federal procurement for VA, DOD, IHS), Patient Care Medical, Life Biologics, Medstream Healthcare Solutions, and Best Buy Medical Canada, while building a contract sales team across the U.S. Pricing is not publicly disclosed, but products are positioned within U.S. reimbursement frameworks. Non-dilutive revenue includes R&D grants from the U.S. Department of Defense ($425,000) and NRC IRAP ($200,000).

In 2025, Kane Biotech underwent significant restructuring, winding down its STEM Animal Health contract manufacturing subsidiary to focus exclusively on revyve-related commercial opportunities. The company is publicly listed on the TSX Venture Exchange (KNE) and US OTC (KNBIF), has 11-50 employees, and is led by interim CEO Dr. Robert Huizinga with Board Chair Philip Renaud holding approximately 27.75% ownership (up to 31.70% on convertible exercise). FY2025 revenue was $427,869 USD with Q1 2026 revenue of $43,218 USD, reflecting the strategic exit from animal health operations. The company has raised approximately $5.3 million through 2024-2026, primarily via insider-led private placements.

Short descriptiontext

Kane Biotech is a Winnipeg-based biotechnology company commercializing FDA 510(k)-cleared revyve wound care products that use its proprietary coactiv+® platform and DispersinB® enzyme to disrupt biofilms in chronic wounds, burns, and surgical sites, primarily serving U.S. and Canadian healthcare providers through distributor and federal procurement channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWinnipeg, Canada
HQ citystring
Winnipeg
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biofilm disruption technology, antimicrobial wound care, wound healing gel, tissue regeneration solutions, medical device commercialization
Industry2 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code4 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical Appliance and Supplies Manufacturing339113
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing33911
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
Product category
Advanced Wound Care Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales - revyve Wound Care Portfolio
TypeOne Time License
Description

Revenue generated from the sale of FDA 510(k) cleared and Health Canada approved wound care products including revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. The company is in early commercialization phase with multiple distribution partnerships.

globenewswire.com
2R&D Funding and Government Grants
TypeProfessional Services
Description

Non-dilutive funding received from government agencies including NRC IRAP ($200,000 for product expansion) and U.S. Department of Defense ($425,000 for DispersinB Hydrogel clinical development)

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1revyve™ / revyve®
Description

Wound care product line including Antimicrobial Wound Gel, Antimicrobial Wound Gel Spray, and Antimicrobial Skin and Wound Cleanser. FDA 510(k) cleared and Health Canada approved products for treating chronic wounds, burns, and various dermal lesions.

kanebiotech.com
+3 more records
Core offering1 text field

Kane Biotech develops and commercializes FDA 510(k)-cleared and Health Canada-approved antimicrobial wound care products under the revyve® brand, built on its proprietary coactiv+® platform and DispersinB® biofilm-disrupting enzyme. The portfolio includes revyve Antimicrobial Wound Gel, Wound Gel Spray, and Skin and Wound Cleanser, with additional products in development for surgical, acne, and tissue regeneration applications. The company sells primarily through medical distributors and federal procurement channels to healthcare providers treating chronic and burn wounds.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Kane Biotech is a biotechnology company commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. The company's core product portfolio centers on the revyve product line, which includes three FDA 510(k) cleared products: revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. The revyve products utilize Kane's proprietary coactiv+ technology platform combined with thermo-reversible gel formulations that provide antimicrobial activity while maintaining a moist wound healing environment. The company is also developing additional wound care and surgical products including coactiv+ Antimicrobial Surgical Hydrogel and DispersinB Hydrogel. In late 2024, Kane announced the acquisition of FB Dermatology, acquiring the patented FLETECH technology for tissue regeneration and dermatology applications.

Product and service3 records
1revyve Antimicrobial Wound Gel
CategoryAdvanced wound care — antimicrobial gel
Description

A thermo-reversible antimicrobial wound gel combining Kane's patented coactiv+ technology, providing a moist wound healing environment with easy application, firm adherence, and easy rinse-off. FDA 510(k) cleared and Health Canada approved for wound care.

2revyve Antimicrobial Wound Gel Spray
CategoryAdvanced wound care — antimicrobial spray
Description

A novel non-aerosol gel spray providing zero-contact antimicrobial treatment for traumatic, large surface, and hard-to-reach wounds. Thick gel adheres strongly and is designed for painless delivery and removal. FDA 510(k) cleared and Health Canada approved.

3revyve Antimicrobial Skin and Wound Cleanser
CategoryAdvanced wound care — wound cleanser
Description

FDA 510(k)-cleared wound cleanser for mechanical cleansing, moistening, debriding, and removal of foreign material including microorganisms and debris from acute and chronic dermal lesions including pressure ulcers, diabetic foot ulcers, burns, and surgical wounds.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Collaborative research partnership for Frontiers in Antibiotics publication on revyve's effectiveness against antibiotic-tolerant biofilms. Researchers contributed to study demonstrating gel's efficacy in in vitro and ex vivo models.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-10
Description

Marathon Medical Corporation, a federally verified Service-Disabled Veteran-Owned Small Business (SDVOSB), signed as distribution partner to provide access to U.S. Veterans Affairs, Department of Defense, and Indian Health Services markets through established federal procurement contracts. The partnership significantly expands Kane's ability to penetrate U.S. government healthcare systems.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-02-20
Description

Co-authorship on International Wound Journal publication demonstrating revyve's efficacy and safety. Researchers from Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery contributed to peer-reviewed validation of thermo-reversible wound gel technology.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-19
Description

Non-exclusive distribution/sales agreement signed for revyve Antimicrobial Wound Gel product line. Patient Care Medical distributes within Louisiana, Mississippi, and Gulf Coast region specializing in in-hospital and mobile wound care facilities. Initial shipments expected in near term.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-19
Description

Non-exclusive distribution/sales agreement for revyve Antimicrobial Wound Gel product line. Life Biologics distributes nationally in advanced wound care market, expanding Kane's presence across targeted U.S. sales channels and geographic markets.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-12
Description

Non-exclusive distribution/sales agreement for revyve Antimicrobial Wound Gel product line in the United States. Medstream Healthcare Solutions is based in Dorval, Florida and supports Kane's U.S. commercialization restart.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-12
Description

Canadian distribution partner converted to non-exclusive arrangement for revyve Antimicrobial Wound Gel products, supporting broader national penetration with targeted sales and sampling initiatives.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

Proposed acquisition of FB Dermatology, an Italian biotech company with operations in Italy, Australia, and New Zealand. Deal valued at $2.5 million including cash, shares, and warrants. Expected to leverage FB Dermatology's patented FLETECH technology for tissue regeneration and dermatology solutions to enhance Kane's market presence and product commercialization.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.S. regenerative medicine company specializing in skin substitutes and active wound care (Apligraf, Dermagraft, PuraPly). Comparable as a direct competitor in advanced/regenerative wound care with overlapping indications (diabetic foot ulcers, venous leg ulcers).

TypeBroad incumbent
Description

Global medical device company with the Advanced Wound Management division; competes directly in wound gels, antimicrobial dressings, and skin substitutes. Comparable as a broad incumbent offering overlapping chronic wound care solutions through established hospital and distribution channels.

TypeDirect peer
Description

French specialty wound care company with a portfolio of antimicrobial dressings (UrgoClean, UrgoStart) targeting chronic wounds including diabetic foot ulcers. Direct peer in advanced wound care with overlapping indications and similar biofilm-focused product positioning.

TypeEmerging player
Description

Smaller specialty wound care company with hydrogel and barrier products; comparable as a niche emerging player in advanced wound care with overlapping product formats (hydrogel-based) and similar target customer segments (podiatry, wound clinics).

TypeDirect peer
Description

Danish medical device company with a major wound and skin care division including antimicrobial dressings and biofilm-targeting products (e.g., Biatain). Direct peer in advanced wound care with strong U.S. distribution and a focus on chronic wounds similar to Kane's target segments.

TypeBroad incumbent
Description

Medical device company with a strong regenerative tissue and wound care portfolio (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel). Broad incumbent offering overlapping solutions to hospitals and burn centers — relevant for Kane's burn care segment with revyve Gel Spray.

TypeBroad incumbent
Description

Swedish wound care and surgical solutions company with Mepilex, Mepitel, and other advanced wound dressings including antimicrobial variants. Comparable broad incumbent in the same hospital and outpatient wound care channels Kane targets with revyve.

TypeDirect peer
Description

U.S. company commercializing placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical recovery. Direct peer in advanced wound care with a focus on chronic, non-healing wounds similar to Kane's revyve product line.

TypeDirect peer
Description

Specialty medical device company focused on advanced wound care, ostomy, and continence care. Direct competitor in antimicrobial wound dressings and gels; Kane's VP Patti Burke-Martin previously held senior roles at ConvaTec, reflecting the overlapping customer base (podiatrists, wound care nurses, hospitals).

TypeBroad incumbent
Description

Spun off from 3M, Solventum's Health Care segment includes a large advanced wound care portfolio (Tegaderm, Cavilon). Comparable broad incumbent with significant U.S. distribution, formulary access, and clinician relationships in the same channels Kane is building.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds29 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kane Biotech

Advanced Wound Care Deviceskanebiotech.com

Kane Biotech is a Winnipeg-based biotechnology company commercializing FDA 510(k)-cleared revyve wound care products that use its proprietary coactiv+® platform and DispersinB® enzyme to disrupt biofilms in chronic wounds, burns, and surgical sites, primarily serving U.S. and Canadian healthcare providers through distributor and federal procurement channels.

What Kane Biotech does

Kane Biotech Inc. is a Canadian biotechnology company headquartered in Winnipeg, Manitoba, that develops and commercializes technologies to prevent and disperse microbial biofilms in human wound care. The company's commercial portfolio centers on the revyve® product line, which combines a proprietary coactiv+® antimicrobial platform with thermo-reversible gel chemistry that transitions from liquid to gel at body temperature for easy application, wound adherence, and atraumatic removal. The revyve portfolio comprises three FDA 510(k)-cleared products (Antimicrobial Wound Gel, Antimicrobial Wound Gel Spray, and Antimicrobial Skin and Wound Cleanser) and two Health Canada approvals, targeting chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcers), burn wounds, and surgical sites. The company also develops the DispersinB® enzyme for biofilm disruption and acquired FB Dermatology's FLETECH tissue regeneration technology in January 2025.

The business model is a regulated medical device sales operation in early commercialization, generating revenue through one-time product sales of FDA-cleared wound care products via a multi-channel distribution model. As of Q1 2026, Kane Biotech had signed non-exclusive distribution and sales agent agreements with Marathon Medical Corporation (federal procurement for VA, DOD, IHS), Patient Care Medical, Life Biologics, Medstream Healthcare Solutions, and Best Buy Medical Canada, while building a contract sales team across the U.S. Pricing is not publicly disclosed, but products are positioned within U.S. reimbursement frameworks. Non-dilutive revenue includes R&D grants from the U.S. Department of Defense ($425,000) and NRC IRAP ($200,000).

In 2025, Kane Biotech underwent significant restructuring, winding down its STEM Animal Health contract manufacturing subsidiary to focus exclusively on revyve-related commercial opportunities. The company is publicly listed on the TSX Venture Exchange (KNE) and US OTC (KNBIF), has 11-50 employees, and is led by interim CEO Dr. Robert Huizinga with Board Chair Philip Renaud holding approximately 27.75% ownership (up to 31.70% on convertible exercise). FY2025 revenue was $427,869 USD with Q1 2026 revenue of $43,218 USD, reflecting the strategic exit from animal health operations. The company has raised approximately $5.3 million through 2024-2026, primarily via insider-led private placements.

Kane Biotech firmographics

Firmographics
Name
Kane Biotech
Legal name
Kane Biotech Inc.
Website
https://kanebiotech.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Kane Biotech is a Winnipeg-based biotechnology company commercializing FDA 510(k)-cleared revyve wound care products that use its proprietary coactiv+® platform and DispersinB® enzyme to disrupt biofilms in chronic wounds, burns, and surgical sites, primarily serving U.S. and Canadian healthcare providers through distributor and federal procurement channels.
Ownership category
akta.pro rank

Kane Biotech industry classification

Industry
Product category
Advanced Wound Care Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (33911)
SIC
Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Biofilm disruption technology
  • Antimicrobial wound care
  • Wound healing gel
  • Tissue regeneration solutions
  • Medical device commercialization

Where Kane Biotech is headquartered

Location

Headquarters

HQ city
Winnipeg
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Kane Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Product Sales - revyve Wound Care Portfolio: Revenue generated from the sale of FDA 510(k) cleared and Health Canada approved wound care products including revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. The company is in early commercialization phase with multiple distribution partnerships.
  2. R&D Funding and Government Grants: Non-dilutive funding received from government agencies including NRC IRAP ($200,000 for product expansion) and U.S. Department of Defense ($425,000 for DispersinB Hydrogel clinical development)

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Kane Biotech product offering

Product offering

Core offering

Kane Biotech develops and commercializes FDA 510(k)-cleared and Health Canada-approved antimicrobial wound care products under the revyve® brand, built on its proprietary coactiv+® platform and DispersinB® biofilm-disrupting enzyme. The portfolio includes revyve Antimicrobial Wound Gel, Wound Gel Spray, and Skin and Wound Cleanser, with additional products in development for surgical, acne, and tissue regeneration applications. The company sells primarily through medical distributors and federal procurement channels to healthcare providers treating chronic and burn wounds.

Product overview

Kane Biotech is a biotechnology company commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. The company's core product portfolio centers on the revyve product line, which includes three FDA 510(k) cleared products: revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser. The revyve products utilize Kane's proprietary coactiv+ technology platform combined with thermo-reversible gel formulations that provide antimicrobial activity while maintaining a moist wound healing environment. The company is also developing additional wound care and surgical products including coactiv+ Antimicrobial Surgical Hydrogel and DispersinB Hydrogel. In late 2024, Kane announced the acquisition of FB Dermatology, acquiring the patented FLETECH technology for tissue regeneration and dermatology applications.

Differentiator

Problem solved

Functional benefit

Brands

  • revyve™ / revyve®: Wound care product line including Antimicrobial Wound Gel, Antimicrobial Wound Gel Spray, and Antimicrobial Skin and Wound Cleanser. FDA 510(k) cleared and Health Canada approved products for treating chronic wounds, burns, and various dermal lesions.
  • coactiv+™ / coactiv+®
  • DispersinB®
  • FLETECH

Products and services

  • revyve Antimicrobial Wound Gel A thermo-reversible antimicrobial wound gel combining Kane's patented coactiv+ technology, providing a moist wound healing environment with easy application, firm adherence, and easy rinse-off. FDA 510(k) cleared and Health Canada approved for wound care.
  • revyve Antimicrobial Wound Gel Spray A novel non-aerosol gel spray providing zero-contact antimicrobial treatment for traumatic, large surface, and hard-to-reach wounds. Thick gel adheres strongly and is designed for painless delivery and removal. FDA 510(k) cleared and Health Canada approved.
  • revyve Antimicrobial Skin and Wound Cleanser FDA 510(k)-cleared wound cleanser for mechanical cleansing, moistening, debriding, and removal of foreign material including microorganisms and debris from acute and chronic dermal lesions including pressure ulcers, diabetic foot ulcers, burns, and surgical wounds.

Companies that use Kane Biotech

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Kane Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Kane Biotech partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered supporting, core and major.

  • University of ManitobasupportingStrategic or Co-development Partner · 17 March 2026Collaborative research partnership for Frontiers in Antibiotics publication on revyve's effectiveness against antibiotic-tolerant biofilms. Researchers contributed to study demonstrating gel's efficacy in in vitro and ex vivo models.
  • Marathon Medical CorporationcoreChannel Partner/ Reseller/ Distributor · 10 March 2026Marathon Medical Corporation, a federally verified Service-Disabled Veteran-Owned Small Business (SDVOSB), signed as distribution partner to provide access to U.S. Veterans Affairs, Department of Defense, and Indian Health Services markets through established federal procurement contracts. The partnership significantly expands Kane's ability to penetrate U.S. government healthcare systems.
  • University of Miami Miller School of MedicinesupportingStrategic or Co-development Partner · 20 February 2026Co-authorship on International Wound Journal publication demonstrating revyve's efficacy and safety. Researchers from Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery contributed to peer-reviewed validation of thermo-reversible wound gel technology.
  • Patient Care MedicalcoreChannel Partner/ Reseller/ Distributor · 19 February 2026Non-exclusive distribution/sales agreement signed for revyve Antimicrobial Wound Gel product line. Patient Care Medical distributes within Louisiana, Mississippi, and Gulf Coast region specializing in in-hospital and mobile wound care facilities. Initial shipments expected in near term.
  • Life BiologicscoreChannel Partner/ Reseller/ Distributor · 19 February 2026Non-exclusive distribution/sales agreement for revyve Antimicrobial Wound Gel product line. Life Biologics distributes nationally in advanced wound care market, expanding Kane's presence across targeted U.S. sales channels and geographic markets.
  • Medstream Healthcare SolutionscoreChannel Partner/ Reseller/ Distributor · 12 February 2026Non-exclusive distribution/sales agreement for revyve Antimicrobial Wound Gel product line in the United States. Medstream Healthcare Solutions is based in Dorval, Florida and supports Kane's U.S. commercialization restart.
  • Best Buy Medical CanadacoreChannel Partner/ Reseller/ Distributor · 12 February 2026Canadian distribution partner converted to non-exclusive arrangement for revyve Antimicrobial Wound Gel products, supporting broader national penetration with targeted sales and sampling initiatives.
  • FB DermatologymajorStrategic or Co-development Partner · 12 November 2024Proposed acquisition of FB Dermatology, an Italian biotech company with operations in Italy, Australia, and New Zealand. Deal valued at $2.5 million including cash, shares, and warrants. Expected to leverage FB Dermatology's patented FLETECH technology for tissue regeneration and dermatology solutions to enhance Kane's market presence and product commercialization.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Kane Biotech competitors and assessment

Company assessment

Direct peers

  • Organogenesis: U.S. regenerative medicine company specializing in skin substitutes and active wound care (Apligraf, Dermagraft, PuraPly). Comparable as a direct competitor in advanced/regenerative wound care with overlapping indications (diabetic foot ulcers, venous leg ulcers).
  • Urgo Medical: French specialty wound care company with a portfolio of antimicrobial dressings (UrgoClean, UrgoStart) targeting chronic wounds including diabetic foot ulcers. Direct peer in advanced wound care with overlapping indications and similar biofilm-focused product positioning.
  • Coloplast: Danish medical device company with a major wound and skin care division including antimicrobial dressings and biofilm-targeting products (e.g., Biatain). Direct peer in advanced wound care with strong U.S. distribution and a focus on chronic wounds similar to Kane's target segments.
  • MiMedx: U.S. company commercializing placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical recovery. Direct peer in advanced wound care with a focus on chronic, non-healing wounds similar to Kane's revyve product line.
  • ConvaTec: Specialty medical device company focused on advanced wound care, ostomy, and continence care. Direct competitor in antimicrobial wound dressings and gels; Kane's VP Patti Burke-Martin previously held senior roles at ConvaTec, reflecting the overlapping customer base (podiatrists, wound care nurses, hospitals).

Broad incumbents

  • Smith & Nephew: Global medical device company with the Advanced Wound Management division; competes directly in wound gels, antimicrobial dressings, and skin substitutes. Comparable as a broad incumbent offering overlapping chronic wound care solutions through established hospital and distribution channels.
  • Integra LifeSciences: Medical device company with a strong regenerative tissue and wound care portfolio (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel). Broad incumbent offering overlapping solutions to hospitals and burn centers — relevant for Kane's burn care segment with revyve Gel Spray.
  • Mölnlycke Health Care: Swedish wound care and surgical solutions company with Mepilex, Mepitel, and other advanced wound dressings including antimicrobial variants. Comparable broad incumbent in the same hospital and outpatient wound care channels Kane targets with revyve.
  • 3M Health Care (Solventum): Spun off from 3M, Solventum's Health Care segment includes a large advanced wound care portfolio (Tegaderm, Cavilon). Comparable broad incumbent with significant U.S. distribution, formulary access, and clinician relationships in the same channels Kane is building.

Emerging players

  • Carnegie Pharmaceuticals: Smaller specialty wound care company with hydrogel and barrier products; comparable as a niche emerging player in advanced wound care with overlapping product formats (hydrogel-based) and similar target customer segments (podiatry, wound clinics).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Kane Biotech social profiles

Digital presence

Kane Biotech compliance and trust

Trust signal

Compliance3 records

Kane Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kane Biotech leadership team

Management profile

Number of profiles

Profiles10 records

Kane Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Kane Biotech funding detail

Funding detail

Funding overview

Funding rounds29 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kane Biotech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kane Biotech

What does Kane Biotech do?

Kane Biotech develops and commercializes FDA 510(k)-cleared and Health Canada-approved antimicrobial wound care products under the revyve® brand, built on its proprietary coactiv+® platform and DispersinB® biofilm-disrupting enzyme. The portfolio includes revyve Antimicrobial Wound Gel, Wound Gel Spray, and Skin and Wound Cleanser, with additional products in development for surgical, acne, and tissue regeneration applications. The company sells primarily through medical distributors and federal procurement channels to healthcare providers treating chronic and burn wounds.

Is Kane Biotech a public or private company?

Kane Biotech is a public company. It is classified as public and is currently operating.

When was Kane Biotech founded?

Kane Biotech was founded in 2005. It employs 11 to 50 people.

Where is Kane Biotech based?

Kane Biotech is headquartered in Winnipeg, Canada, in the North America region.

How does Kane Biotech make money?

Two revenue lines are on record. Product Sales - revyve Wound Care Portfolio is the primary driver. The others are R&D Funding and Government Grants.

Who are Kane Biotech's main competitors?

Direct peers on record are Organogenesis, Urgo Medical, Coloplast, MiMedx and ConvaTec. Broad incumbents are Smith & Nephew, Integra LifeSciences, Mölnlycke Health Care and 3M Health Care (Solventum). Carnegie Pharmaceuticals is listed as an emerging player.

Does Kane Biotech have an API?

No public API is recorded for Kane Biotech.

What industry is Kane Biotech in?

Kane Biotech's product category is Advanced Wound Care Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingKane Biotech Study Links Revyve Wound Gel to 43.9% Mean Wound Area ReductionKane Biotech published results from a prospective observational study of 17 adults with 28 chronic wounds, finding adjunctive Revyve wound gel reduced wound size, improved bed condition, and lowered pain. The study followed patients for up to 12 weeks, with median wound duration of 22 months before treatment. The authors called for larger controlled studies.TradingViewKane Biotech Inc. (KNE) Takes $250K Unsecured Insider LoanKane Biotech accepted a $250K unsecured, non-interest-bearing loan from its board chair, repayable on demand, to support working capital. The loan is a related-party transaction exempt from valuation and approval due to its size, and funds operations, implying immediate cash needs ahead of financing.Financial PostKane Biotech to Present Clinical Data and Showcase revyve® Product Line at SAWC Fall 2026Kane Biotech will attend SAWC Fall 2026 in Las Vegas, presenting clinical data on its revyve wound-care products and showcasing the product line. The company plans to meet with distributors to expand commercial reach in the U.S. and other markets.Seeking AlphaKane Biotech Inc. (KNE:CA) Shareholder/Analyst Call TranscriptKane Biotech's chairman Philip Renaud addressed shareholders, reaffirming his commitment and the company's focus on wound care via its FDA and Health Canada approved revyve product platform. He cited positive feedback from doctors and patients on reordering and ongoing evaluation of value-enhancing opportunities.AInvestKane Biotech: A Real Product At A Penny-Stock Valuation, Waiting To Prove RevenueKane Biotech will hold a commercial update on September 16, with Q2 2026 revenue of C$8,143 and C$939,000 cash. The company's FDA/Health Canada-approved wound gel shows 97% ulcer reduction but faces structural sales challenges. The next two to four quarters will test whether rebuilt distribution generates recurring revenue.AInvestKane Biotech Got Another Distribution Deal. Its Quarterly Revenue Is Still $8,143Kane Biotech signed a non-exclusive Ontario distributor deal with Ontario Medical Supply for its revyve wound-care products. The company reported $8,143 in Q2 revenue and a $833,636 net loss, with $855,000 in cash. The deal grants access to Ontario's home-care market but carries no sales obligations.Financial PostKane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.Kane Biotech announced a partnership with Ontario Medical Supply Inc. to expand its Canadian commercial reach. The company's wound care products, including revyve gel and spray, are FDA 510(k) cleared and Health Canada approved. The collaboration aims to support home healthcare and community care across Ontario.TradingViewKane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.Kane Biotech entered a non-exclusive distribution agreement with Ontario Medical Supply Inc. to sell its revyve Antimicrobial Wound Gel and Spray in Canada. The products are U.S. FDA 510(k) cleared and Health Canada approved, and OMS will support sales through its wound care activities. The deal aims to expand access to revyve across Canada.Financial PostKane Biotech Announces Second Quarter 2026 Financial ResultsKane Biotech Inc. (TSX-V:KNE) reported second-quarter 2026 results on August 27, 2026, showing revenue of $8,143 versus $27,997 in the prior year, and a net loss of $833,636 versus $348,541. Cash at June 30, 2026 was $854,729. The company said it is expanding distribution in Canada and the U.S., with clinical evaluations underway and a scientific advisory board meeting planned for the fourth quarter.YahooKane Biotech Announces Engagement of DNA AdvisorsKane Biotech Inc. has retained DNA Advisors Inc. as its exclusive financial advisor to conduct a comprehensive strategic review evaluating potential partnerships, financing initiatives, acquisitions, and other corporate transactions aimed at enhancing shareholder value. The review process will assess alternatives that may strengthen the company's position in biofilm science and advanced wound care. The company noted that its revyve Antimicrobial Wound Gel products received FDA 510(k) clearance and Health Canada approval, with commercial activities in the US and Canada having commenced in 2026.